Literature DB >> 21074072

[Diabetes mellitus and cardiovascular risk. Is integrated therapy of type 2 diabetes and cardiovascular risk factors necessary?].

Domingo Orozco Beltrán1, Carlos de la Sen Fernández, Vicente Gil Guillén, Concepción Carratalá Munuera, Jorge Navarro Pérez.   

Abstract

Cardiovascular disease (CVD) is the first cause of death in the Spanish population among both diabetics and non-diabetics. In diabetes, CVD is between 2 and 4 times more frequent, earlier and more aggressive. With current measures, approximately 50% of CVD can be prevented. The risk factors for CVD in diabetes are hypertension, dyslipidemia, smoking, obesity and sedentariness. More than 80% of patient with type 2 diabetes have hypertension and dyslipidemia and approximately 15% continue to smoke. However, all these factors are controlled in at least 10%. Although dyslipidemia is the most influential and least treated factor, the greatest benefit for CVD prevention is obtained with integrated intervention on all risk factors, reducing blood pressure to below 140/80 mmHg, low-density lipoprotein cholesterol (LDL-c) to below 100 mg/dl, encouraging smoking cessation, regular physical activity and maintaining a healthy weight (BMI < 25 kg/m²). In secondary prevention or persons with microvascular disease, the targets may be stricter (blood pressure 130/80 mmHg and LDL-c 80 mg/dl). Drug treatment should always include an angiotensin converting-enzyme inhibitor or an angiotensin II receptor antagonist and a statin. Aspirin should be reserved for patients in secondary prevention or with very high CV risk. Consequently, interventions should be prioritized according to the foreseeable risk for each patient, which can be estimated through the SCORE scale or other scales such as Regicor or UKPDS, with a SCORE > 5% indicating high risk. These high-risk patients should receive personalized care.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21074072      PMCID: PMC8171390          DOI: 10.1016/S0212-6567(10)70004-4

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  30 in total

Review 1.  [Cardiovascular disease in diabetes mellitus].

Authors:  Francisco Javier Ampudia-Blasco; Jorge Navarro
Journal:  Med Clin (Barc)       Date:  2002-03-09       Impact factor: 1.725

2.  [Calibrating the SCORE cardiovascular risk chart for use in Spain].

Authors:  Susana Sans; Anthony P Fitzgerald; David Royo; Ronan Conroy; Ian Graham
Journal:  Rev Esp Cardiol       Date:  2007-05       Impact factor: 4.753

3.  The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain.

Authors:  José R Banegas; Onofre Vegazo; Pedro Serrano; Emilio Luengo; Teresa Mantilla; Raúl Fernández; Fernando Civeira
Journal:  Atherosclerosis       Date:  2005-12-15       Impact factor: 5.162

4.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

5.  Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.

Authors:  Ivan Tkác
Journal:  Diabetes Res Clin Pract       Date:  2009-12       Impact factor: 5.602

6.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

7.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Authors:  R C Turner; H Millns; H A Neil; I M Stratton; S E Manley; D R Matthews; R R Holman
Journal:  BMJ       Date:  1998-03-14

8.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

Authors:  Giuseppe Mancia; Stéphane Laurent; Enrico Agabiti-Rosei; Ettore Ambrosioni; Michel Burnier; Mark J Caulfield; Renata Cifkova; Denis Clément; Antonio Coca; Anna Dominiczak; Serap Erdine; Robert Fagard; Csaba Farsang; Guido Grassi; Hermann Haller; Antony Heagerty; Sverre E Kjeldsen; Wolfgang Kiowski; Jean Michel Mallion; Athanasios Manolis; Krzysztof Narkiewicz; Peter Nilsson; Michael H Olsen; Karl Heinz Rahn; Josep Redon; José Rodicio; Luis Ruilope; Roland E Schmieder; Harry A J Struijker-Boudier; Pieter A Van Zwieten; Margus Viigimaa; Alberto Zanchetti
Journal:  Blood Press       Date:  2009       Impact factor: 2.835

9.  Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Authors:  Hisao Ogawa; Masafumi Nakayama; Takeshi Morimoto; Shiro Uemura; Masao Kanauchi; Naofumi Doi; Hideaki Jinnouchi; Seigo Sugiyama; Yoshihiko Saito
Journal:  JAMA       Date:  2008-11-09       Impact factor: 56.272

10.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina
Journal:  Eur Heart J       Date:  2007-08-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.